Novel and emerging therapies for cholestatic liver diseases

Jordan Goldstein, Cynthia Levy

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

While bile acids are important for both digestion and signalling, hydrophobic bile acids can be harmful, especially when in high concentrations. Mechanisms for the protection of cholangiocytes against bile acid cytotoxicity include negative feedback loops via farnesoid X nuclear receptor (FXR) activation, the bicarbonate umbrella, cholehepatic shunting and anti-inflammatory signalling, among others. By altering or overwhelming these defence mechanisms, cholestatic diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) can further progress to biliary cirrhosis, end-stage liver disease and death or liver transplantation. While PBC is currently treated with ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), many fail treatment, and we have yet to find an effective therapy for PSC. Novel therapies under evaluation target nuclear and surface receptors including FXR, transmembrane G-protein–coupled receptor 5 (TGR5), peroxisome proliferator-activated receptor (PPAR) and pregnane X receptor (PXR). Modulation of these receptors leads to altered bile composition, decreased cytotoxicity, decreased inflammation and improved metabolism. This review summarizes our current understanding of the role of bile acids in the pathophysiology of cholestatic liver diseases, presents the rationale for already approved medical therapies and discusses novel pharmacologic therapies under investigation.

Original languageEnglish (US)
Pages (from-to)1520-1535
Number of pages16
JournalLiver International
Volume38
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Liver Diseases
Bile Acids and Salts
Cytoplasmic and Nuclear Receptors
Sclerosing Cholangitis
Cholangitis
Therapeutics
Ursodeoxycholic Acid
Peroxisome Proliferator-Activated Receptors
End Stage Liver Disease
Biliary Liver Cirrhosis
Bicarbonates
Bile
Liver Transplantation
Digestion
Anti-Inflammatory Agents
Inflammation

Keywords

  • nuclear receptor
  • primary biliary cholangitis
  • primary sclerosing cholangitis
  • therapy

ASJC Scopus subject areas

  • Hepatology

Cite this

Novel and emerging therapies for cholestatic liver diseases. / Goldstein, Jordan; Levy, Cynthia.

In: Liver International, Vol. 38, No. 9, 01.09.2018, p. 1520-1535.

Research output: Contribution to journalReview article

Goldstein, Jordan ; Levy, Cynthia. / Novel and emerging therapies for cholestatic liver diseases. In: Liver International. 2018 ; Vol. 38, No. 9. pp. 1520-1535.
@article{ebf77d256b6947e8b49917b9f6c78b44,
title = "Novel and emerging therapies for cholestatic liver diseases",
abstract = "While bile acids are important for both digestion and signalling, hydrophobic bile acids can be harmful, especially when in high concentrations. Mechanisms for the protection of cholangiocytes against bile acid cytotoxicity include negative feedback loops via farnesoid X nuclear receptor (FXR) activation, the bicarbonate umbrella, cholehepatic shunting and anti-inflammatory signalling, among others. By altering or overwhelming these defence mechanisms, cholestatic diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) can further progress to biliary cirrhosis, end-stage liver disease and death or liver transplantation. While PBC is currently treated with ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), many fail treatment, and we have yet to find an effective therapy for PSC. Novel therapies under evaluation target nuclear and surface receptors including FXR, transmembrane G-protein–coupled receptor 5 (TGR5), peroxisome proliferator-activated receptor (PPAR) and pregnane X receptor (PXR). Modulation of these receptors leads to altered bile composition, decreased cytotoxicity, decreased inflammation and improved metabolism. This review summarizes our current understanding of the role of bile acids in the pathophysiology of cholestatic liver diseases, presents the rationale for already approved medical therapies and discusses novel pharmacologic therapies under investigation.",
keywords = "nuclear receptor, primary biliary cholangitis, primary sclerosing cholangitis, therapy",
author = "Jordan Goldstein and Cynthia Levy",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/liv.13880",
language = "English (US)",
volume = "38",
pages = "1520--1535",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Novel and emerging therapies for cholestatic liver diseases

AU - Goldstein, Jordan

AU - Levy, Cynthia

PY - 2018/9/1

Y1 - 2018/9/1

N2 - While bile acids are important for both digestion and signalling, hydrophobic bile acids can be harmful, especially when in high concentrations. Mechanisms for the protection of cholangiocytes against bile acid cytotoxicity include negative feedback loops via farnesoid X nuclear receptor (FXR) activation, the bicarbonate umbrella, cholehepatic shunting and anti-inflammatory signalling, among others. By altering or overwhelming these defence mechanisms, cholestatic diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) can further progress to biliary cirrhosis, end-stage liver disease and death or liver transplantation. While PBC is currently treated with ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), many fail treatment, and we have yet to find an effective therapy for PSC. Novel therapies under evaluation target nuclear and surface receptors including FXR, transmembrane G-protein–coupled receptor 5 (TGR5), peroxisome proliferator-activated receptor (PPAR) and pregnane X receptor (PXR). Modulation of these receptors leads to altered bile composition, decreased cytotoxicity, decreased inflammation and improved metabolism. This review summarizes our current understanding of the role of bile acids in the pathophysiology of cholestatic liver diseases, presents the rationale for already approved medical therapies and discusses novel pharmacologic therapies under investigation.

AB - While bile acids are important for both digestion and signalling, hydrophobic bile acids can be harmful, especially when in high concentrations. Mechanisms for the protection of cholangiocytes against bile acid cytotoxicity include negative feedback loops via farnesoid X nuclear receptor (FXR) activation, the bicarbonate umbrella, cholehepatic shunting and anti-inflammatory signalling, among others. By altering or overwhelming these defence mechanisms, cholestatic diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) can further progress to biliary cirrhosis, end-stage liver disease and death or liver transplantation. While PBC is currently treated with ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), many fail treatment, and we have yet to find an effective therapy for PSC. Novel therapies under evaluation target nuclear and surface receptors including FXR, transmembrane G-protein–coupled receptor 5 (TGR5), peroxisome proliferator-activated receptor (PPAR) and pregnane X receptor (PXR). Modulation of these receptors leads to altered bile composition, decreased cytotoxicity, decreased inflammation and improved metabolism. This review summarizes our current understanding of the role of bile acids in the pathophysiology of cholestatic liver diseases, presents the rationale for already approved medical therapies and discusses novel pharmacologic therapies under investigation.

KW - nuclear receptor

KW - primary biliary cholangitis

KW - primary sclerosing cholangitis

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85052227358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052227358&partnerID=8YFLogxK

U2 - 10.1111/liv.13880

DO - 10.1111/liv.13880

M3 - Review article

C2 - 29758112

AN - SCOPUS:85052227358

VL - 38

SP - 1520

EP - 1535

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 9

ER -